Co-Diagnostics Malaria Test Ready for Validation

Share Article

Co-Diagnostics, Inc. announced today that the company has completed work on its real-time PCR test for malaria, and it is now ready for in-field validation.

Co-Diagnostics, Inc. announced today that the company has completed work on its real-time PCR test for malaria, and it is now ready for in-field validation.

The real-time PCR malaria test is built on the company’s patent-pending CoPrimers™ technology. CoPrimers™ avoid both false-negatives and false-positives, common in other PCR tests, due to their unique ability to prevent the formation of the phenomenon known as “primer-dimers.” CoPrimers’™ unique design was the subject of a favorably reviewed article in the March 2014 issue of The Journal of Molecular Diagnostics, and further product advances will be the theme of an upcoming paper, soon to be submitted for publication. Both papers are authored by Co-Diagnostics founder Dr. Brent Satterfield.

Co-Diagnostics CEO Dwight Egan commented, “Malaria is a pervasive problem, particularly in countries that lack access to high-quality, accurate and affordable diagnostics. We are confident that our low-cost, highly sensitive PCR tests will have an impact on the diagnosis of a disease that continues to challenge health organizations and governments in many emerging nations.

About Co-Diagnostics
Co-Diagnostics, Inc., a molecular diagnostics company, is a Utah corporation based in Sandy, Utah that develops, manufactures and markets fully-integrated DNA-based test systems. The company’s intellectual property is built on mathematical principles, creating proprietary algorithms in a unique, DNA-based diagnostics system that it deems to be superior, both in cost and speed of development, to other diagnostics systems, both in the US and abroad.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Dwight Egan
Visit website